Alicia McElhaney

Recent Articles By The Author

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan CEO Heather Bresch's father sponsored a bill that made it easier for generic drugs to be substituted back in 1986. This helped Mylan become the largest generic manufacturer.

CytomX Soars on Bristol-Myers Partnership

CytomX Soars on Bristol-Myers Partnership

Shares of the biotech, which researches cancer drugs, were up nearly 30% ahead of market's open.

Fred's Bolsters Board as Walgreens, Rite Aid Near FTC Nod

Fred's Bolsters Board as Walgreens, Rite Aid Near FTC Nod

As Walgreens Boots Alliance's WBA acquisition of Rite Aid nears FTC approval, Fred's has added several directors with retail experience to its board.

Valeant Shares Skyrocket After Hours on ValueAct Buy

Valeant Shares Skyrocket After Hours on ValueAct Buy

The move comes just days after Bill Ackman's Pershing Square exited the stock.

Insys Falls on Earnings Delay

Insys Falls on Earnings Delay

Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.

Health Care Investors Attempt to Parse Trump Budget

Health Care Investors Attempt to Parse Trump Budget

Universal Health Services and Acadia Healthcare stand to benefit from the proposal.

Valeant Shares Still Reeling From Ackman Exit

Valeant Shares Still Reeling From Ackman Exit

Bill Ackman's Pershing Square took a $2.8 billion loss on the investment.

Shanda Goes Active on Community Health

Shanda Goes Active on Community Health

The Chinese investment firm has a 13.74% stake in the debt-laden hospital system.

Here's Why Valeant's Stock Had Another Disastrous Week

Here's Why Valeant's Stock Had Another Disastrous Week

The company's shares lost more than 10% of their value this week, though they rebounded on Friday.

Incyte Pops on Continued Gilead Takeout Speculation

Incyte Pops on Continued Gilead Takeout Speculation

Shares were up 8% during intraday trading.